Fig. 8
From: Identification of small molecules capable of enhancing viral membrane fusion
Effect of selected compounds on SARS-CoV-2 and IAV. A SARS-CoV-2 was grown at a multiplicity of infection (MOI) of 0.01 in Vero E6 cells for 48 h in the absence or presence of ethaverine, rabeprazole, or ethynylestradiol at the indicated concentrations. Next, supernatants were collected and tittered by standard plaque assay in Vero E6 cells. Bars show the average plaque forming units (pfu) and standard deviation of at least three independent experiments. Dots represent individual experiments. No statistical differences, based on a two-tailed homoscedastic t-test, were found between treated and mock-treated samples. B IAV/WSN/33, at an MOI of 0.001, was used to infect Madin-Darby canine kidney (MDCK) cells. IAV was incubated in the absence or presence of ethaverine, rabeprazole, or ethynylestradiol at the indicated concentrations for 48 h. Next, supernatants were collected and tittered by the 50% Tissue Culture Infective Dose (TCID50) method in MDCK cells. Bars show the average plaque forming units (pfu) and standard deviation of at least three independent experiments. Dots represent individual experiments. Based on a two-tailed homoscedastic t-test, no statistical differences were found between treated and mock-treated samples